Profusa (NASDAQ:PFSA) Major Shareholder Financial Lp Hrt Sells 42,411 Shares

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt sold 42,411 shares of Profusa stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $0.89, for a total value of $37,745.79. Following the sale, the insider directly owned 74,198 shares in the company, valued at approximately $66,036.22. This trade represents a 36.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, August 12th, Financial Lp Hrt acquired 5,585 shares of Profusa stock. The stock was acquired at an average cost of $0.96 per share, with a total value of $5,361.60.
• On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The stock was acquired at an average cost of $0.95 per share, with a total value of $1,299.60.
• On Monday, August 3rd, Financial Lp Hrt bought 14,556 shares of Profusa stock. The shares were acquired at an average cost of $0.96 per share, for a total transaction of $13,973.76.
• On Wednesday, July 29th, Financial Lp Hrt bought 1,310 shares of Profusa stock. The shares were acquired at an average cost of $1.01 per share, for a total transaction of $1,323.10.

Profusa Stock Performance

Shares of PFSA stock opened at $0.90 on Friday. Profusa, Inc. has a 1 year low of $0.81 and a 1 year high of $1,297.50. The firm has a market capitalization of $170,962.00, a PE ratio of -0.00 and a beta of 0.52. The stock has a fifty day moving average of $2.73 and a two-hundred day moving average of $24.89.

Profusa’s stock is scheduled to reverse split on the morning of Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 16th.

Analysts Set New Price Targets

Several equities analysts have commented on PFSA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.